Trials / Completed
CompletedNCT00214773
Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)
MPS VI Clinical Surveillance Program (CSP)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 237 (actual)
- Sponsor
- BioMarin Pharmaceutical · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The objectives of this program are: to further characterize the natural progression of MPS VI disease; to generate and disseminate information on the care and management of MPS VI patients to clinical and medical professionals; to provide a resource to physicians and patients by providing information for optimizing patient care based on aggregate data; to characterize the clinical response to long-term Naglazyme® (galsulfase) treatment; to further characterize the long-term safety of Naglazyme® treatment.
Conditions
Timeline
- Start date
- 2005-07-01
- Primary completion
- 2020-05-01
- Completion
- 2020-05-01
- First posted
- 2005-09-22
- Last updated
- 2021-04-05
Locations
50 sites across 13 countries: United States, Australia, Austria, Belgium, France, Germany, Ireland, Italy, Lithuania, Netherlands, Portugal, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00214773. Inclusion in this directory is not an endorsement.